Angola Pharmaceuticals & Healthcare Report

Published 13 November 2014

  • 61 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Angola Pharmaceuticals & Healthcare Report

BMI View: The Angolan government ' s initiatives to make healthcare more affordable, coupled with the municipalisation of health services, will lead to greater access to medical services and increase pharmaceutical spending in Angola. A new medicine depot is a step in the right direction towards improving the traditionally difficult operating environment of the country's pharmaceutical and healthcare markets. However, poor patent protection, a lack of hospitals and clinics, and the threat of counterfeit medicines will deter foreign drugmakers looking to operate in the Angolan pharmaceutical and healthcare sector.

Headline Expenditure Forecasts

  • Pharmaceuticals: AOA29.12bn (USD302mn) in 2013 to AOA33.33bn (USD339mn) in 2014; +14.5% in local currency and +12.4% in US dollar terms. 

  • Healthcare: AOA449.55bn (USD4.66bn) in 2013 to AOA505.3bn (USD5.14bn) in 2014; +12.4% in local currency and +10.4% in US dollar terms.

Risk/Reward Index

Angola's Pharmaceutical Risk/Reward Index (RRI) score for Q115 is 33.3, an improvement from last quarter's score of 32.0. It also moves up five places from last quarter, making it the 22nd most attractive pharmaceutical market in the Middle East and Africa region.

Key Trends And Developments

October 2014

The Government of Cuanza Sul Province, Angola, has announced it will build health facilities in the administrative capital Sumbe to improve the quality of healthcare services in the province, reports Angola Press Agency, citing Vice Governor for Social and Political Affairs Maria de Lourdes Veiga. There is a need for the government to invest in healthcare infrastructure, as well as the training of medical staff, stressed Veiga. Construction of the new provincial hospital in Sumbe, and rehabilitation and upgrading of the primary health units are expected to be complete by 2015, according to Veiga.

Angola's State Secretary for Health Carlos Alberto Masseca has announced a plan to create a national drug registry and system for medicines...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Angola 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2010-2018)
19
Key Risks To BMI's Forecast Scenario
19
Macroeconomic Forecasts
21
Economic Analysis
21
Table: Economic Activity (Angola 2009-2019)
24
Industry Risk Reward Ratings
25
Middle East & Africa Risk/Reward Index
25
Angola Risk/Reward Index
32
Rewards
32
Risks
33
Market Overview
34
Industry Trends And Developments
36
Epidemiology
36
Clinical Trials
40
Regulatory Development
41
Regulatory Development
41
Intellectual Property Issues
42
Pricing Regime
42
Competitive Landscape
44
Company Developments
45
Company Profile
47
Nova Angom-dica
47
Demographic Forecast
49
Table: Population Headline Indicators (Angola 1990-2025)
50
Table: Key Population Ratios (Angola 1990-2025)
50
Table: Urban/Rural Population & Life Expectancy (Angola 1990-2025)
52
Table: Population By Age Group (Angola 1990-2025)
52
Table: Population By Age Group % (Angola 1990-2025)
53
Glossary
54
Methodology
56
Pharmaceutical Expenditure Forecast Model
56
Healthcare Expenditure Forecast Model
56
Notes On Methodology
57
Risk/Reward Index Methodology
58
Index Overview
59
Table: Pharmaceutical Risk/Reward Index Indicators
59
Indicator Weightings
60

The Angola Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Angola Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Angola pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Angola, to test other views - a key input for successful budgeting and strategic business planning in the Angolan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Angolan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Angola.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc